KIT and neoplasm: Sunitinib, a MKI targeting VEGFR1,2,3, Kit, PDGFRA/B, FLT-3 and RET has also shown efficacy in the reduction of the primary tumor proliferation and the tumor vasculature in cell-derived osteosarcoma mouse models [82].